Text Size
29 studies found for:    " April 29, 2009":" May 29, 2009"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]

Modify this search | How to Use Search Results

Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Cancel
Rank Status Study
1 Completed
Has Results 		A Clinical Trial Comparing the Tolerability of Etravirine to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Treatment-naive HIV-1 Infected Patients
Conditions: HIV Infection;   HIV;   Acquired Immunodeficiency Syndrome
Interventions: Drug: etravirine (ETR, TMC125);   Drug: efavirenz (EFV)
2 Completed Empowerment Intervention for Young Women - Phase I
Conditions: HIV;   Empowerment;   HIV Infections
Intervention: Behavioral: Prevention Empowerment Intervention for Young Women
3 Completed Linkage to Care - Part II
Conditions: HIV;   Care-seeking;   HIV Infections
Interventions: Other: Case Management;   Other: Snowball sampling;   Other: Referral Lists
4 Completed TMC125-TiDP2-C238: An Exploratory Pharmacokinetics, Safety and Anti-HIV Activity Study of Etravirine (ETR) When Given With Boosted Atazanavir (ATV/Rtv) at Two Different Doses and 1 Nucleoside Reverse Transcriptase Inhibitor (NRTI) in Treatment Experienced HIV Patients
Conditions: HIV Infections;   Acquired Immunodeficiency Syndrome
Interventions: Drug: 48 weeks ATV/rtv 300/100mg once daily + ETR 200mg twice daily;   Drug: TDF 300mg;   Drug: ATV/rtv 400/100mg;   Drug: ATV/rtv 300/100mg
5 Active, not recruiting Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy
Conditions: Accelerated Phase Chronic Myelogenous Leukemia;   Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome;   Acute Undifferentiated Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Grade III Lymphomatoid Granulomatosis;   Adult Langerhans Cell Histiocytosis;   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Aggressive NK-cell Leukemia;   AIDS-related Diffuse Large Cell Lymphoma;   AIDS-related Diffuse Mixed Cell Lymphoma;   AIDS-related Diffuse Small Cleaved Cell Lymphoma;   AIDS-related Immunoblastic Large Cell Lymphoma;   AIDS-related Lymphoblastic Lymphoma;   AIDS-related Malignancies;   AIDS-related Small Noncleaved Cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Chronic Eosinophilic Leukemia;   Chronic Myelomonocytic Leukemia;   Chronic Neutrophilic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   Clear Cell Renal Cell Carcinoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   de Novo Myelodysplastic Syndromes;   Essential Thrombocythemia;   Extramedullary Plasmacytoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   HIV Infection;   HIV-associated Hodgkin Lymphoma;   Intraocular Lymphoma;   Isolated Plasmacytoma of Bone;   Light Chain Deposition Disease;   Mast Cell Leukemia;   Myelodysplastic Syndrome With Isolated Del(5q);   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Myeloid/NK-cell Acute Leukemia;   Nodal Marginal Zone B-cell Lymphoma;   Noncutaneous Extranodal Lymphoma;   Osteolytic Lesions of Multiple Myeloma;   Peripheral T-cell Lymphoma;   Plasma Cell Neoplasm;   Polycythemia Vera;   Post-transplant Lymphoproliferative Disorder;   Previously Treated Myelodysplastic Syndromes;   Primary Myelofibrosis;   Primary Systemic Amyloidosis;   Progressive Hairy Cell Leukemia, Initial Treatment;   Prolymphocytic Leukemia;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Renal Cell Cancer;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Refractory Multiple Myeloma;   Relapsing Chronic Myelogenous Leukemia;   Stage IV Renal Cell Cancer;   T-cell Large Granular Lymphocyte Leukemia;   Testicular Lymphoma;   Unspecified Adult Solid Tumor, Protocol Specific;   Waldenström Macroglobulinemia
Interventions: Drug: sunitinib malate;   Other: pharmacological study;   Other: laboratory biomarker analysis
6 Recruiting Evaluating an Exercise Program to Reduce Cardiovascular Risk Factors in Children Infected With HIV
Conditions: HIV;   Acquired Immunodeficiency Syndrome;   Cardiovascular Diseases
Interventions: Behavioral: Exercise Program;   Behavioral: Control Group
7 Unknown † Raltegravir in the Swiss HIV Cohort Study
Condition: HIV Infection
Intervention: Drug: Raltegravir
8 Completed Early Immune Responses to Vaccination - A Substudy to HVTN 205
Condition: HIV Infections
Interventions: Biological: JS7 DNA vaccine;   Biological: MVA/HIV62 vaccine
9 Active, not recruiting New Era Study: Treatment With Multi Drug Class (MDC) HAART in HIV Infected Patients
Condition: HIV Infections
Intervention: Drug: 2 NRTI + 1 PI/r + Maraviroc + Raltegravir
10 Completed TMC207-TiDP13-C117: Interaction Study in Human Immunodeficiency Virus-type 1 (HIV-1) Infected Patients With Nevirapine (NVP)
Condition: HIV Infections
Intervention: Drug: TMC207; nevirapine
11 Recruiting Addition of Ezetimibe (Ezetrol®) to Ongoing Therapy With Rosuvastatin (Crestor®) in HIV Positive Patients Not Reaching Cholesterol Targets
Conditions: Hypercholesterolemia;   HIV Infections
Interventions: Drug: Ezetimibe;   Drug: Rosuvastatin (standard care)
12 Active, not recruiting Prevalence and Predictors of Neurocognitive Impairment Among HIV-infected Patients
Conditions: HIV Infections;   Memory
Intervention:
13 Completed Safety and Immunogenicity of TBC-M4, a MVA HIV Vaccine Alone or in a Prime-Boost Regimen With ADVAX DNA HIV Vaccine
Condition: HIV Infections
Interventions: Biological: ADVAX;   Biological: TBC-M4;   Other: Placebo
14 Unknown † Exercise for Patients With HIV Infections
Conditions: HIV Infections;   Lipodystrophy;   Inflammation
Intervention: Behavioral: Exercise
15 Active, not recruiting HIV and Kidney Function Study
Conditions: HIV Infections;   AIDS
Intervention:
16 Completed Prevalence and Determinants of Chronic Obstructive Pulmonary Disease (COPD) in HIV+ Patients
Conditions: HIV Infections;   COPD
Intervention:
17 Active, not recruiting Safety and Efficacy of GS-9350-boosted Atazanavir Compared to Ritonavir-boosted Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults
Condition: HIV-1 Infection
Interventions: Drug: 150 mg tablet GS- 9350;   Drug: ritonavir 100 mg capsule;   Drug: atazanavir 300 mg capsule;   Drug: emtricitabine/tenofovir DF 200/300 mg tablet;   Drug: ritonavir placebo;   Drug: GS-9350 placebo
18 Withdrawn Trial of TDF/FTC + Raltegravir Versus TDF/FTC + Efavirenz in HIV-1-Infected Women
Condition: HIV-1 Infections
Interventions: Drug: TDF/FTC Once-Daily + Raltegravir 400 mg Orally Twice-Daily;   Drug: TDF/FTC + Efavirenz (Atripla) Once-Daily
19 Completed Interactions of Hepatitis C Viral (HCV) Dynamics and Immune Activation in HIV Coinfected Patients During HCV Treatment
Conditions: Human Immunodeficiency Virus;   Chronic Hepatitis C
Interventions: Drug: pegylated interferon-alpha (Pegasys);   Drug: ribavirin (COPEGUS)
20 Terminated PEPI-TiDP23-C104 is a First in Human Study With a Single Dose Escalation Part and a Multiple Dosing Part for Compounds TMC589337 and TMC589354.
Condition: HIV Infections
Intervention: Drug: TMC589337, TMC589354, TMC310911, placebo
To Top

Previous Page Studies Shown (1-20) Next Page (21-29) Show next page of results
† Indicates status has not been verified in more than two years